# Patient Care Plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Leonard Nimoy (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML017-SYN-TD
- Date: 2014-02-10
- Fictional facility: St. Posthumous Health Center
- Fictional author: Carla Benedetti, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

## What we are working on

- Breathlessness keeps him from walking any distance, and he uses a wheelchair at airports **S**
- Wants other smokers to quit before their lungs are damaged, and wants to keep working on his photography and writing **S**

## Your goals

- CAT score at least 2 points lower by the three-month review. Target: 2014-05-12. Recorded outcome: CAT fell from 22 to 15. **S**
- 6-minute walk distance at least 30 meters farther after pulmonary rehabilitation. Target: 2014-05-12. Recorded outcome: 270 m at entry and 330 m at exit. **S**
- No moderate or severe exacerbation over the six months after starting maintenance therapy. Target: 2014-08-11. Recorded outcome: No exacerbation, oral corticosteroid course, antibiotic course, or emergency visit in six months. **S**
- Correct soft mist inhaler technique and a daily maintenance dose. Target: 2014-03-10. Recorded outcome: Correct technique on demonstration and no missed doses by dose counter at four weeks. **S**

## What we agreed to do

- Start tiotropium-olodaterol 2.5/2.5 mcg soft mist inhaler, two inhalations each morning, keep albuterol as needed, and teach and check inhaler technique at every visit; no inhaled corticosteroid while there are no exacerbations and blood eosinophils are below 300 per microliter. Guideline: Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, 2025 report (2025); CMID: Clinical Monitoring Intelligence Database, chronic obstructive pulmonary disease monograph (2026) **S**
- Pulmonology consultation to confirm the GOLD grade and group, review the inhaler choice and the place of an inhaled corticosteroid, assess oxygen need at rest and on exertion, interpret the alpha-1 antitrypsin result, and advise on pulmonary rehabilitation and lung cancer screening. Guideline: Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, 2025 report (2025); CMID: Clinical Monitoring Intelligence Database, chronic obstructive pulmonary disease monograph (2026) **S**
- Outpatient pulmonary rehabilitation (mMRC 2 or more, GOLD 2 to 4), with a 6-minute walk test at entry and exit and a home exercise plan afterwards. Guideline: Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, 2025 report (2025); CMID: Clinical Monitoring Intelligence Database, chronic obstructive pulmonary disease monograph (2026); Pulmonary Rehabilitation for Adults with Chronic Respiratory Disease: An Official American Thoracic Society Clinical Practice Guideline (2023) **S**
- At every visit: CAT, mMRC, exacerbations in the past 12 months, GOLD group, pulse oximetry, smoking status, BMI, and inhaler technique. Spirometry at diagnosis and at least yearly; alpha-1 antitrypsin once; blood eosinophils at baseline and before any change in inhaled corticosteroid; arterial blood gas only if resting saturation is 92 percent or less; long-term oxygen only for resting saturation of 88 percent or less confirmed twice at least three weeks apart; ECG and cardiovascular risk at baseline. Guideline: Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, 2025 report (2025); CMID: Clinical Monitoring Intelligence Database, chronic obstructive pulmonary disease monograph (2026); Home Oxygen Therapy for Adults with Chronic Lung Disease: An Official American Thoracic Society Clinical Practice Guideline (2020) **S**
- Written COPD action plan: what an exacerbation looks like (more breathlessness, more or discolored sputum), when to use extra albuterol, and when to call the clinic the same day or go to emergency care. Guideline: Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, 2025 report (2025); CMID: Clinical Monitoring Intelligence Database, chronic obstructive pulmonary disease monograph (2026) **S**
- Lung cancer screening reviewed and not offered: he quit smoking more than 15 years ago, so he does not meet the USPSTF criteria despite more than 20 pack-years. Guideline: CMID: Clinical Monitoring Intelligence Database, chronic obstructive pulmonary disease monograph (2026); Lung Cancer: Screening (2021) **S**
- Vaccines for COPD: yearly influenza (high dose at 65 and older), PCV20 once, RSV once at 75 and older, COVID-19 by CDC guidance, Tdap every ten years, and recombinant zoster. Guideline: CMID: Clinical Monitoring Intelligence Database, chronic obstructive pulmonary disease monograph (2026); Adult Immunization Schedule by Age (2026) **S**
- Comorbidity and mood screening at intake and yearly (depression, anxiety, cardiovascular disease, osteoporosis, reflux, sleep, nutrition), and advance care planning at the wellness visit. Guideline: Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, 2025 report (2025); CMID: Clinical Monitoring Intelligence Database, chronic obstructive pulmonary disease monograph (2026) **S**

## Follow-up

- 2014-02-10: New patient visit for COPD and breathlessness walking any distance **S**
- 2014-03-10: Four-week COPD review after starting dual bronchodilator therapy, with pulmonology consultation **S**
- 2014-05-12: Three-month COPD review after pulmonary rehabilitation **S**
- 2014-08-11: Six-month COPD review **S**
- 2014-10-06: Subsequent annual wellness visit **S**

This teaching document does not replace care from a qualified clinician.
